CBP/p300-IN-20

Cat. No.:	HY-151812
Molecular Formula:	$C_{22}H_{19}ClF_3N_5O_2$
Molecular Weight:	477.87
Target:	Histone Acetyltransferase; Epigenetic Reader Domain
Pathway:	Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CBP/p300-IN-20 is a potent and selective p300/CBP inhibitor, with a pIC_{50} of 10.1 for p300. CBP/p300-IN-20 can be used for the research of cancer[1].
IC_{50} & Target	CBP/p300 10.1 (pIC_{50})
In Vitro	CBP/p300-IN-20 (compound 28) decreases Myc protein in cell-based cMyc HTRF assay, with a pEC_{50} of 8.5[1]. CBP/p300-IN-20 (1 μM) shows 97% inhibition for p300 and 80% inhibition for CPB[1]. CBP/p300-IN-20 (0.3-1000 nM; 2 h) decreases H3K18 and H3K27 acetylation without affecting H3K9 acetylation and total H3 in COLO 320HSR cells[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	CBP/p300-IN-20 (compound 28) (0.54 mg/kg; i.v.) exhibits C_{max} (210 ng/mL), $AUC_{0\rightarrow\infty}$ (102 h•ng/mL), CL (95 mL/min/kg), and $T_{1/2}$ (0.3 h) in rats[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis[1]

Cell Line:	COLO 320HSR cells
Concentration:	0.3, 1, 3, 10, 30, 100, 300, 1000 nM
Incubation Time:	2 hours
Result:	Caused a rapid concentration-dependent decrease in H3K18 and H3K27 acetylation without affecting H3K9 acetylation and total H3.

REFERENCES

[1]. Tian X, et, al. Discovery of Proline-Based p300/CBP Inhibitors Using DNA-Encoded Library Technology in Combination with High-Throughput Screening. J Med Chem. 2022 Nov 10;65(21):14391-14408.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA